MYC and diffuse large B-cell lymphoma: This is because most of what we know about DHLs is based on cases with MYC/BCL2 DHL, which has an inferior prognosis when treated with regimens for diffuse large B-cell lymphoma (DLBCL) and has a very high recurrence rate with a reported median survival of only 0.2 to 1.5 years [1, 6, 7].